Product information and disease descriptionProduct descriptionProduct information
Product comparison
8 evidence topics · 8 sources
Approved and investigational therapies for GA named by the sponsor
Competition from approved products stated by the sponsor
Sponsor contrast with C3 and C5 inhibitors: target and functional outcome
Sponsor characterization of comparator photoreceptor analyses
Sponsor claim of vision preservation and the phase 2 primary endpoint result on which it rests
Independent systematic review: no peer-reviewed clinical results for C1q inhibition
“Although these therapies have progressed to clinical stages, no peer-reviewed publications reporting their clinical results are available to date. According to registry and sponsor-reported information, C1q blockade with ANX007 has progressed furthest among these candidates, advancing to Phase 3 trials following neuroprotective signals in Phase 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As these results are not yet supported by peer-reviewed publications, they were not included in the evidence synthesis and are reported here for context only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Head-to-head trial data against pegcetacoplan or avacincaptad pegol
No evidence found.